<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769314</url>
  </required_header>
  <id_info>
    <org_study_id>BA2005/21/02</org_study_id>
    <nct_id>NCT00769314</nct_id>
  </id_info>
  <brief_title>Phase 3 Clinical Study for the Treatment of Cold Sore</brief_title>
  <acronym>LIP</acronym>
  <official_title>A Randomised, Double-Blind, Single Dose, One-Day Early Administration, Multicentre Study Comparing the Efficacy and Safety of Acyclovir Lauriad® 50 mg Muco-adhesive Buccal Tablet to Matching Placebo, in the Treatment of Herpes Labialis in Immunocompetent Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Onxeo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Onxeo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy of a single dose of acyclovir Lauriad® 50mg muco-adhesive buccal
      tablet versus a single dose of matching placebo on the primary vesicular lesion of cold sore.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Healing (TTH) of Vesicular Primary Lesion</measure>
    <time_frame>Assessed from time of treatment initiation through Day 14</time_frame>
    <description>Healing was defined as the loss of crust (erythema may be present) as assessed by the investigator. TTH was the time from treatment initiation to healing as defined above and was assessed from the time of treatment initiation through Day 14. The primary vesicular lesion was the first developed lesion located on the lip and was not to have extended more than 1 cm outside the lip.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abortion of Primary Lesions</measure>
    <time_frame>Assessed from the time of treatment initiation through Day 14</time_frame>
    <description>Aborted lesions were defined as herpetic lesions preceded by prodromal symptoms that did not progress beyond the papule stage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTH of Non-primary Lesions (Aborted Lesions Excluded)</measure>
    <time_frame>Assessed from the time of treatment initiation through Day 14</time_frame>
    <description>TTH of non-primary lesions was defined as the time from treatment initiation to healing of all non-primary vesicular lesions. Non-primary lesions were those that developed in addition to and/or in 1 or more days after the primary vesicular lesion and that were located at least 1 cm from the primary lesion. Aborted lesions were not included in this parameter. TTH was to be assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Episode (DOE)</measure>
    <time_frame>Assessed from initiation of treatment to Day 14</time_frame>
    <description>For patients who experienced a vesicular lesion, DOE was defined as the time from treatment initiation to healing of primary and secondary vesicular lesions (loss of crust). For subjects whose primary and secondary lesions were not vesicular in nature, DOE was defied as the time from treatment initiation to return to normal skin or to cessation of symptoms, whichever came last.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cessation of Symptoms</measure>
    <time_frame>Assessed from time of treatment initiation through Day 14</time_frame>
    <description>Time to cessation of symptoms was defined as the time from treatment initiation to cessation of all symptoms: pain, burning, itching, tingling, tenderness and discomfort. It was to be assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTH of Aborted Primary Lesions</measure>
    <time_frame>Assessed from time of treatment initiation through Day 14</time_frame>
    <description>TTH of aborted primary lesions was defined as the time from treatment initiation to healing of the primary lesion (erythema or papule) or cessation of symptoms, whichever came last. It was to be assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recurrence of Non-aborted Lesions During 9-month Follow-up</measure>
    <time_frame>From time of initial healing through the 9-month follow-up</time_frame>
    <description>Time to recurrence was the time from the healing of all lesions of the initial episode to the occurrence of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Incidence of Recurrence of Non-aborted Lesions During 9-month Follow-up</measure>
    <time_frame>From time of initial healing through the 9-month follow-up</time_frame>
    <description>Recurrence was the occurrence of new lesions and was evaluated in a subgroup of patients who agreed to record recurrences during the 9-month follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Intensity (Visual Analogue Scale [VAS])</measure>
    <time_frame>Assessed on Days 1, 3, 5, 7 and 14 (or within 24 hours of healing)</time_frame>
    <description>Patients were asked to place a tick mark on a 10 centimeter VAS indicating their symptom intensity. Scale ratings ranged from a minimum of 0 (none at all) to a maximum of 10 (worst possible). The location of the tick mark from &quot;0&quot; was measured in millimeters (0 - 100) and recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Treatment</measure>
    <time_frame>Assessed on Day 14 (or within 24 hours of healing)</time_frame>
    <description>At the end of study (Day 14 [or within 24 hours of healing]), patients were asked whether they were satisfied with treatment (yes/no).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Efficacy of the Treatment</measure>
    <time_frame>Assessed on Day 14 (or within 24 hours of healing)</time_frame>
    <description>At the end of study (Day 14 [ or within 24 hours of healing]), patients were asked to rate efficacy of treatment using a 4-point scale (inactive, mildly active, moderately active, or very active).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1727</enrollment>
  <condition>Herpes Labialis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acyclovir Lauriad 50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir Lauriad</intervention_name>
    <description>50 mg muco-adhesive buccal tablets, single application on the gum</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 mg muco-adhesive buccal tablets, single application on the gum</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of recurrent herpes labialis lesions where:

               -  At least 50% of previous episodes produced classical lesions to the vesicular
                  stage (i.e. episodes that progressed through macula, papule, vesicle, crust and
                  healed);

               -  Prodromal symptoms (itching, tingling, pain etc.) should precede herpes labialis
                  lesions in at least 50% of the previous herpes episodes

          -  Good general health (ECOG &lt; 2), immunocompetent

          -  Signed and dated written informed consent - Women of childbearing potential must have
             effective contraception method

        Exclusion Criteria:

          -  More than 50% of recurrences that aborted spontaneously in the past 12 months

          -  Primary herpes lesion outside the lips (e.g. nose, chin, etc.)

          -  Abnormal peri-oral skin condition that might affect the normal course of cold sores
             (e.g. eczema, psoriasis…)

          -  Oral diseases whose prodromal symptoms may mimick those of herpes labialis, including
             recurrent oral aphthous disease

          -  Oral diseases that might interfere with the evaluation of the efficacy or safety of
             the treatments, including gingivitis, parondotis, mucositis, oropharyngeal
             candidiasis…

          -  History of infection known to be resistant to acyclovir family agents

          -  Previous vaccination against herpes

          -  Concomitant treatment likely to interfere with acyclovir

          -  Allergy to any acyclovir containing agents

          -  Immunocompromised condition, including HIV+

          -  Unability to properly understand protocol requirements, to follow the study
             procedures, to complete the patient diary or to start the self-initiation of the
             treatment

          -  Upper full or partial dentures with acrylic border in the canine fossa

          -  Milk allergy or known history of hypersensitivity to one of the components of the
             products

          -  Rare hereditary problems of galactose intolerance.

          -  Lactase enzyme deficiency or glucose galactose malabsorption

          -  Clinically significant abnormal level of serum creatinine

          -  Patients whose occupations make them unlikely to return to the clinic within 24h of
             treatment initiation

          -  Pregnancy or breast-feeding

          -  Investigational drug or immunomodulator treatment in the 30 days prior randomisation

          -  Prior enrollment in this study

          -  Participation in another therapeutic trial evaluating new drugs or which could
             interfere with the evolution of herpes labialis or the evaluation of the drug in the
             study within preceding 30 day.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radiant Research, Inc.,</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.,</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Private Practice</name>
      <address>
        <city>San Fransisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Front Range Clinical Research</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Family Health,</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinvest, a Division of Banyan Group, Inc.,</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.,</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies, Ltd., LLP.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taylor Square Private Clinic</name>
      <address>
        <city>Sydney</city>
        <zip>Darlinghurst, NSW 2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Brunswick Medical Centre</name>
      <address>
        <city>Sydney</city>
        <zip>QLD 4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Teaching Hospital, Dep. Of Dermatology</name>
      <address>
        <city>Opava</city>
        <zip>128 08 Praha 2</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U zastavky 16</name>
      <address>
        <city>Opava</city>
        <zip>747 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central military hospital Dept. of Dermatology</name>
      <address>
        <city>Praha</city>
        <zip>169 02 Praha 6</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bulovka 3rd Clinic of Inf. Diseases</name>
      <address>
        <city>Praha</city>
        <zip>180 81 Praha 8</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bulovka Dept. of Dermatology</name>
      <address>
        <city>Praha</city>
        <zip>180 81 Praha 8</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital St Jacques Service de Dermatologie</name>
      <address>
        <city>Besancon</city>
        <zip>25030 BESANCON CEDEX</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Martigues</city>
        <zip>13500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Fournier, Service de dermatologie</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital L'Archet 2, Service de Dermatologie</name>
      <address>
        <city>Nice</city>
        <zip>06202 NICE Cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon, Dermatology department</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis Paris, Service de Dermatologie 1</name>
      <address>
        <city>Paris</city>
        <zip>75475 PARIS Cedex 10</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Stomatologie et chirurgie Maxilo-Faciale.Hôpital de la pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75651 Paris Cedex 13</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord, Service de dermatologie</name>
      <address>
        <city>St. Etienne</city>
        <zip>42065 St ETIENNE Cedex 2</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital TROUSSEAU</name>
      <address>
        <city>Tours</city>
        <zip>37044 TOURS Cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Dörzapf und Partner</name>
      <address>
        <city>Augsburg</city>
        <zip>86153</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin Klinik für Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polikum Friedenau</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis</name>
      <address>
        <city>Berlin</city>
        <zip>12353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laserclinic Drs. Steinert</name>
      <address>
        <city>Biberach</city>
        <zip>88400</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Dermatologie des Universitätsklinikums Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis</name>
      <address>
        <city>Frankfurt</city>
        <zip>60326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raiffeisenstr. 15b</name>
      <address>
        <city>Oberkirch</city>
        <zip>77704</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Erhard-Platz 9-11</name>
      <address>
        <city>Rodgau-Dudenhofen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Dermatologii Collegium Medicum</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-096</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Diabet</name>
      <address>
        <city>Chrzanów</city>
        <zip>32-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naukowo-Badawczy i Naukowo-Dydaktyczny Ośrodek Dermatologii Estetycznej, Dermatochirurgii i Fotodermatologii</name>
      <address>
        <city>Gdynia</city>
        <zip>81-366</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej GCP Dobra Praktyka Lekarska</name>
      <address>
        <city>Grudziądz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Atopia, Al. J.</name>
      <address>
        <city>Kraków</city>
        <zip>31-159</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zakład Opieki Zdrowotnej Specjalistyczna Przychodnia Lekarska Medikard</name>
      <address>
        <city>Płock</city>
        <zip>09-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zakład Opieki Zdrowotnej &quot;Nasz Lekarz&quot; Praktyka Grupowa Lekarzy Rodzinnych z Przychodnią Specjalistyczną</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Internistyczny</name>
      <address>
        <city>Warszawa</city>
        <zip>03-003</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Praktyka Lekarska Iga Gilas - Mirkiewicz</name>
      <address>
        <city>Wrocław</city>
        <zip>50-354</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczne Gabinety Lekarskie Dermed</name>
      <address>
        <city>Łódź</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cossington House Surgery</name>
      <address>
        <city>Canterbury</city>
        <zip>CT1 3HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School of Dentistry, Cardiff University</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidley Surgery</name>
      <address>
        <city>East Sussex</city>
        <zip>TN39 5HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sea Road Surgery</name>
      <address>
        <city>East Sussex</city>
        <zip>TN40 1JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saltash Health Centre</name>
      <address>
        <city>Saltash</city>
        <zip>PL12 6DL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <results_first_submitted>October 26, 2011</results_first_submitted>
  <results_first_submitted_qc>November 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 21, 2012</results_first_posted>
  <last_update_submitted>November 21, 2012</last_update_submitted>
  <last_update_submitted_qc>November 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Labialis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were screened beginning March 2007 and the last patient was treated in October 2008. The study was conducted at 47 sites in Australia, the Czech Republic, France, Germany, Poland, the United Kingdom and the United States.</recruitment_details>
      <pre_assignment_details>Per protocol, a total of 1950 patients were to be randomized. Following randomization, patients were not to start treatment until a new labial herpes episode occurred. Thus, of those randomized, only 780 patients were planned to be treated (390 patients per treatment group) and 1170 patients were to be randomized, but not treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acyclovir Lauriad Group</title>
          <description>Acyclovir Lauriad 50mg muco-adhesive tablet</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>muco-adhesive buccal tablet with placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="378">The number of participants started is defined as those that were randomized and received treatment.</participants>
                <participants group_id="P2" count="397">The number of participants started is defined as those that were randomized and received treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="361"/>
                <participants group_id="P2" count="384"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acyclovir Lauriad Group</title>
          <description>Acyclovir Lauriad 50mg muco-adhesive tablet/Intent-to-Treat population</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>muco-adhesive buccal tablet with placebo/Intent-to-Treat population</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="376"/>
            <count group_id="B2" value="395"/>
            <count group_id="B3" value="771"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Data are provided for the Intent-to-Treat population.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="12.97"/>
                    <measurement group_id="B2" value="41.9" spread="13.33"/>
                    <measurement group_id="B3" value="41.0" spread="13.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Data are provided for the Intent-to-Treat population.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="258"/>
                    <measurement group_id="B2" value="271"/>
                    <measurement group_id="B3" value="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Data are provided for the Intent-to-Treat population.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Abortion of Primary Lesions</title>
        <description>Aborted lesions were defined as herpetic lesions preceded by prodromal symptoms that did not progress beyond the papule stage.</description>
        <time_frame>Assessed from the time of treatment initiation through Day 14</time_frame>
        <population>This endpoint was analyzed using the Intent-to-Treat (ITT) population, which consisted of all randomized patients who received at least one dose of study medication and who had complete information recorded for the application time.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Lauriad Group</title>
            <description>Acyclovir Lauriad 50mg muco-adhesive tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>muco-adhesive buccal tablet with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Abortion of Primary Lesions</title>
          <description>Aborted lesions were defined as herpetic lesions preceded by prodromal symptoms that did not progress beyond the papule stage.</description>
          <population>This endpoint was analyzed using the Intent-to-Treat (ITT) population, which consisted of all randomized patients who received at least one dose of study medication and who had complete information recorded for the application time.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aborted Lesions = Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aborted Lesions = No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242"/>
                    <measurement group_id="O2" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aborted Lesions = Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0419</p_value>
            <p_value_desc>p-value &lt; 0.05 considered significant</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Treatment difference</param_type>
            <param_value>0.0685</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0025</ci_lower_limit>
            <ci_upper_limit>0.1339</ci_upper_limit>
            <estimate_desc>Treatment difference was the proportion of patients with aborted lesions in the acyclovir Lauriad group minus the proportion of patients with aborted lesions in the placebo group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TTH of Non-primary Lesions (Aborted Lesions Excluded)</title>
        <description>TTH of non-primary lesions was defined as the time from treatment initiation to healing of all non-primary vesicular lesions. Non-primary lesions were those that developed in addition to and/or in 1 or more days after the primary vesicular lesion and that were located at least 1 cm from the primary lesion. Aborted lesions were not included in this parameter. TTH was to be assessed by the investigator.</description>
        <time_frame>Assessed from the time of treatment initiation through Day 14</time_frame>
        <population>This endpoint was analyzed using a subgroup of patients in the ITT population with non-primary lesions.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Lauriad Group</title>
            <description>Acyclovir Lauriad 50mg muco-adhesive tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>muco-adhesive buccal tablet with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>TTH of Non-primary Lesions (Aborted Lesions Excluded)</title>
          <description>TTH of non-primary lesions was defined as the time from treatment initiation to healing of all non-primary vesicular lesions. Non-primary lesions were those that developed in addition to and/or in 1 or more days after the primary vesicular lesion and that were located at least 1 cm from the primary lesion. Aborted lesions were not included in this parameter. TTH was to be assessed by the investigator.</description>
          <population>This endpoint was analyzed using a subgroup of patients in the ITT population with non-primary lesions.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" lower_limit="5.53" upper_limit="8.70"/>
                    <measurement group_id="O2" value="9.08" lower_limit="7.46" upper_limit="11.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0683</p_value>
            <p_value_desc>p-value &lt; 0.05 considered significant</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Episode (DOE)</title>
        <description>For patients who experienced a vesicular lesion, DOE was defined as the time from treatment initiation to healing of primary and secondary vesicular lesions (loss of crust). For subjects whose primary and secondary lesions were not vesicular in nature, DOE was defied as the time from treatment initiation to return to normal skin or to cessation of symptoms, whichever came last.</description>
        <time_frame>Assessed from initiation of treatment to Day 14</time_frame>
        <population>This endpoint was analyzed using the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Lauriad Group</title>
            <description>Acyclovir Lauriad 50mg muco-adhesive tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>muco-adhesive buccal tablet with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Episode (DOE)</title>
          <description>For patients who experienced a vesicular lesion, DOE was defined as the time from treatment initiation to healing of primary and secondary vesicular lesions (loss of crust). For subjects whose primary and secondary lesions were not vesicular in nature, DOE was defied as the time from treatment initiation to return to normal skin or to cessation of symptoms, whichever came last.</description>
          <population>This endpoint was analyzed using the ITT population.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.57" lower_limit="5.03" upper_limit="6.01"/>
                    <measurement group_id="O2" value="6.38" lower_limit="5.93" upper_limit="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0033</p_value>
            <p_value_desc>p-value &lt; 0.05 considered significant</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cessation of Symptoms</title>
        <description>Time to cessation of symptoms was defined as the time from treatment initiation to cessation of all symptoms: pain, burning, itching, tingling, tenderness and discomfort. It was to be assessed by the investigator.</description>
        <time_frame>Assessed from time of treatment initiation through Day 14</time_frame>
        <population>This endpoint was analyzed using the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Lauriad Group</title>
            <description>Acyclovir Lauriad 50mg muco-adhesive tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>muco-adhesive buccal tablet with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cessation of Symptoms</title>
          <description>Time to cessation of symptoms was defined as the time from treatment initiation to cessation of all symptoms: pain, burning, itching, tingling, tenderness and discomfort. It was to be assessed by the investigator.</description>
          <population>This endpoint was analyzed using the ITT population.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" lower_limit="3.04" upper_limit="4.01"/>
                    <measurement group_id="O2" value="4.16" lower_limit="3.75" upper_limit="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0098</p_value>
            <p_value_desc>p-value &lt; 0.05 considered significant</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TTH of Aborted Primary Lesions</title>
        <description>TTH of aborted primary lesions was defined as the time from treatment initiation to healing of the primary lesion (erythema or papule) or cessation of symptoms, whichever came last. It was to be assessed by the investigator.</description>
        <time_frame>Assessed from time of treatment initiation through Day 14</time_frame>
        <population>This endpoint was analyzed using the subgroup of patients within the ITT population with aborted lesions.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Lauriad Group</title>
            <description>Acyclovir Lauriad 50mg muco-adhesive tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>muco-adhesive buccal tablet with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>TTH of Aborted Primary Lesions</title>
          <description>TTH of aborted primary lesions was defined as the time from treatment initiation to healing of the primary lesion (erythema or papule) or cessation of symptoms, whichever came last. It was to be assessed by the investigator.</description>
          <population>This endpoint was analyzed using the subgroup of patients within the ITT population with aborted lesions.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" lower_limit="2.00" upper_limit="2.96"/>
                    <measurement group_id="O2" value="2.67" lower_limit="2.10" upper_limit="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8005</p_value>
            <p_value_desc>p-value &lt; 0.05 considered significant</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Healing (TTH) of Vesicular Primary Lesion</title>
        <description>Healing was defined as the loss of crust (erythema may be present) as assessed by the investigator. TTH was the time from treatment initiation to healing as defined above and was assessed from the time of treatment initiation through Day 14. The primary vesicular lesion was the first developed lesion located on the lip and was not to have extended more than 1 cm outside the lip.</description>
        <time_frame>Assessed from time of treatment initiation through Day 14</time_frame>
        <population>The modified Intent-to-Treat (mITT) population was the population used for analysis of this endpoint. The mITT population included all randomized patients who received at least one dose of study medication and who reached the vesicular stage (ie, episodes that progressed through macula, papule, vesicle, crust and healing).</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Lauriad Group</title>
            <description>Acyclovir Lauriad 50mg muco-adhesive tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>muco-adhesive buccal tablet with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Healing (TTH) of Vesicular Primary Lesion</title>
          <description>Healing was defined as the loss of crust (erythema may be present) as assessed by the investigator. TTH was the time from treatment initiation to healing as defined above and was assessed from the time of treatment initiation through Day 14. The primary vesicular lesion was the first developed lesion located on the lip and was not to have extended more than 1 cm outside the lip.</description>
          <population>The modified Intent-to-Treat (mITT) population was the population used for analysis of this endpoint. The mITT population included all randomized patients who received at least one dose of study medication and who reached the vesicular stage (ie, episodes that progressed through macula, papule, vesicle, crust and healing).</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" spread="0.18" lower_limit="6.75" upper_limit="7.31"/>
                    <measurement group_id="O2" value="7.32" spread="0.18" lower_limit="6.97" upper_limit="7.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>p-value &lt; 0.05 considered significant</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recurrence of Non-aborted Lesions During 9-month Follow-up</title>
        <description>Time to recurrence was the time from the healing of all lesions of the initial episode to the occurrence of new lesions.</description>
        <time_frame>From time of initial healing through the 9-month follow-up</time_frame>
        <population>This endpoint was analyzed using the follow-up population, a subgroup of the ITT population who continued to the 9 month follow-up and had at least 1 diary assessment during that period. The follow-up population was defined as patients whose lesions were healed at the end of Day 14 and had no recurrence within 15 days of healing of all lesions.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Lauriad Group</title>
            <description>Acyclovir Lauriad 50mg muco-adhesive tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>muco-adhesive buccal tablet with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recurrence of Non-aborted Lesions During 9-month Follow-up</title>
          <description>Time to recurrence was the time from the healing of all lesions of the initial episode to the occurrence of new lesions.</description>
          <population>This endpoint was analyzed using the follow-up population, a subgroup of the ITT population who continued to the 9 month follow-up and had at least 1 diary assessment during that period. The follow-up population was defined as patients whose lesions were healed at the end of Day 14 and had no recurrence within 15 days of healing of all lesions.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.0" spread="19.4" lower_limit="163.0" upper_limit="287.0"/>
                    <measurement group_id="O2" value="165.0" spread="9.3" lower_limit="136.0" upper_limit="203.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0412</p_value>
            <p_value_desc>p-value &lt; 0.05 considered significant</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Incidence of Recurrence of Non-aborted Lesions During 9-month Follow-up</title>
        <description>Recurrence was the occurrence of new lesions and was evaluated in a subgroup of patients who agreed to record recurrences during the 9-month follow-up period.</description>
        <time_frame>From time of initial healing through the 9-month follow-up</time_frame>
        <population>This endpoint was analyzed using the follow-up population, a subgroup of the ITT population who continued to the 9 month follow-up and had at least 1 diary assessment during that period. The follow-up population was defined as patients whose lesions were healed at the end of Day 14 and had no recurrence within 15 days of healing of all lesions.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Lauriad Group</title>
            <description>Acyclovir Lauriad 50mg muco-adhesive tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>muco-adhesive buccal tablet with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Incidence of Recurrence of Non-aborted Lesions During 9-month Follow-up</title>
          <description>Recurrence was the occurrence of new lesions and was evaluated in a subgroup of patients who agreed to record recurrences during the 9-month follow-up period.</description>
          <population>This endpoint was analyzed using the follow-up population, a subgroup of the ITT population who continued to the 9 month follow-up and had at least 1 diary assessment during that period. The follow-up population was defined as patients whose lesions were healed at the end of Day 14 and had no recurrence within 15 days of healing of all lesions.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recurrence during 9-month follow-up = yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrence during 9-month follow-up = no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrence during 9-month follow-up = missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0271</p_value>
            <p_value_desc>p-value &lt; 0.05 considered significant</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Intensity (Visual Analogue Scale [VAS])</title>
        <description>Patients were asked to place a tick mark on a 10 centimeter VAS indicating their symptom intensity. Scale ratings ranged from a minimum of 0 (none at all) to a maximum of 10 (worst possible). The location of the tick mark from &quot;0&quot; was measured in millimeters (0 - 100) and recorded.</description>
        <time_frame>Assessed on Days 1, 3, 5, 7 and 14 (or within 24 hours of healing)</time_frame>
        <population>This endpoint was analyzed using the safety population, which consisted of all randomized patients who took at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Lauriad Group</title>
            <description>Acyclovir Lauriad 50mg muco-adhesive tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>muco-adhesive buccal tablet with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Intensity (Visual Analogue Scale [VAS])</title>
          <description>Patients were asked to place a tick mark on a 10 centimeter VAS indicating their symptom intensity. Scale ratings ranged from a minimum of 0 (none at all) to a maximum of 10 (worst possible). The location of the tick mark from &quot;0&quot; was measured in millimeters (0 - 100) and recorded.</description>
          <population>This endpoint was analyzed using the safety population, which consisted of all randomized patients who took at least 1 dose of study medication.</population>
          <units>units on a scale (0 - 100)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="397"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" spread="22.37"/>
                    <measurement group_id="O2" value="31.1" spread="22.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="22.88"/>
                    <measurement group_id="O2" value="22.9" spread="22.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="17.60"/>
                    <measurement group_id="O2" value="17.3" spread="20.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="13.63"/>
                    <measurement group_id="O2" value="10.7" spread="18.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (or within 24 hours of healing)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="5.14"/>
                    <measurement group_id="O2" value="0.9" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis conducted between treatment groups at Day 1 timepoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5695</p_value>
            <p_value_desc>p-value &lt; 0.05 considered significant</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis conducted between treatment groups at Day 3 timepoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1824</p_value>
            <p_value_desc>p-value &lt; 0.05 considered significant</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis conducted between treatment groups at the Day 5 timepoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0078</p_value>
            <p_value_desc>p-value &lt; 0.05 considered significant</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis conducted between treatment groups at the Day 7 timepoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3303</p_value>
            <p_value_desc>p-value &lt; 0.05 considered significant</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis conducted between treatment groups at the Day 14 timepoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6045</p_value>
            <p_value_desc>p-value &lt; 0.05 considered significant</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Treatment</title>
        <description>At the end of study (Day 14 [or within 24 hours of healing]), patients were asked whether they were satisfied with treatment (yes/no).</description>
        <time_frame>Assessed on Day 14 (or within 24 hours of healing)</time_frame>
        <population>This endpoint was analyzed using the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Lauriad Group</title>
            <description>Acyclovir Lauriad 50mg muco-adhesive tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>muco-adhesive buccal tablet with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Treatment</title>
          <description>At the end of study (Day 14 [or within 24 hours of healing]), patients were asked whether they were satisfied with treatment (yes/no).</description>
          <population>This endpoint was analyzed using the ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Satisfied with treatment = yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297"/>
                    <measurement group_id="O2" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied with treatment = no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <p_value_desc>p-value &lt; 0.05 considered significant</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Efficacy of the Treatment</title>
        <description>At the end of study (Day 14 [ or within 24 hours of healing]), patients were asked to rate efficacy of treatment using a 4-point scale (inactive, mildly active, moderately active, or very active).</description>
        <time_frame>Assessed on Day 14 (or within 24 hours of healing)</time_frame>
        <population>This endpoint was analyzed using the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Lauriad Group</title>
            <description>Acyclovir Lauriad 50mg muco-adhesive tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>muco-adhesive buccal tablet with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessment of Efficacy of the Treatment</title>
          <description>At the end of study (Day 14 [ or within 24 hours of healing]), patients were asked to rate efficacy of treatment using a 4-point scale (inactive, mildly active, moderately active, or very active).</description>
          <population>This endpoint was analyzed using the ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inactive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Midly active</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately active</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very active</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded during the 14 day treatment period.</time_frame>
      <desc>The safety population included all randomized patients who took at least 1 dose of study drug, including 378 patients in the acyclovir Lauriad group and 397 patients in the placebo group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Acyclovir Lauriad Group</title>
          <description>Acyclovir Lauriad 50mg muco-adhesive tablet</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>muco-adhesive buccal tablet with placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>hypersensitivity</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>headache</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="nausea">nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="application Site Pai">Application Site Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="Nasopharyngitis">Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="378"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Pierre ATTALI</name_or_title>
      <organization>BioAlliance Pharma</organization>
      <phone>+33145587600</phone>
      <email>pierre.attali@bioalliancepharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

